代谢功能障碍相关脂肪性肝病患者的肝细胞癌无创风险分层监测
该多中心纵向研究纳入12950例MASLD患者,中位随访47.7个月,109例(0.8%)发生HCC。FIB-4≥3.25或LSM≥20 kPa时年HCC发生率超过1%,作者建议对这类患者提供HCC监测;采用两步法时,FIB-4升高且LSM≥15 kPa提示高HCC风险。
要点
- FIB-4≥3.25患者年HCC发生率为1.18%,超过1%监测阈值。
- LSM≥20 kPa作为独立检测时年HCC发生率超过1%。
- 两步法下FIB-4升高且LSM≥15 kPa年HCC发生率超过1%。
核心结论
- 作者认为应对FIB-4≥3.25或LSM≥20 kPa的MASLD患者提供HCC监测,采用两步法时FIB-4升高且LSM≥15 kPa提示高HCC风险。
研究设计与样本
- 研究为多中心纵向研究,纳入2004年2月至2023年1月美国、欧洲和亚洲16个三级中心的MASLD成人患者。
- 共12950例患者具有FIB-4和肝脏硬度测量(LSM)数据,平均年龄51.7岁,男性占41.1%。
- 主要结局为发生HCC,中位随访47.7个月(IQR 23.3-72.3)。
主要发现
- 随访期间109例(0.8%)发生HCC。
- FIB-4低于低 cut-off(<65岁<1.3,≥65岁<2.0)、低 cut-off至<2.67、2.67至<3.25、≥3.25的患者分别占66.3%、23.9%、3.4%、6.4%,对应年HCC发生率分别为0.07%、0.17%、0.77%、1.18%。
- 作为独立检测,LSM≥10 kPa时年HCC发生率超过0.2%,LSM≥20 kPa时超过1%。
- 仅在FIB-4高于低 cut-off的患者中进一步行LSM的两步法下,LSM≥10 kPa时年HCC发生率超过0.2%,LSM≥15 kPa时超过1%。
关键数值与推荐
- FIB-4低 cut-off为<65岁<1.3、≥65岁<2.0。
- FIB-4≥3.25时年HCC发生率为1.18%。
- LSM≥20 kPa作为独立检测时年HCC发生率超过1%。
- 两步法下FIB-4升高且LSM≥15 kPa时年HCC发生率超过1%。
临床怎么用
- 作者建议对FIB-4≥3.25或LSM≥20 kPa的MASLD患者提供HCC监测。
- 作者指出采用两步法时,FIB-4升高患者中LSM≥15 kPa提示高HCC风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the general population and is the fastest growing cause of hepatocellular carcinoma (HCC). Current guidelines recommend HCC surveillance in patients with cirrhosis when annual HCC incidence exceeds 1% without specifying the role of non-invasive tests in patient selection. OBJECTIVE: To define non-invasive test thresholds to select patients with MASLD for HCC surveillance. DESIGN: A multicentre longitudinal study of adults with MASLD from 16 tertiary centres in the USA, Europe and Asia between February 2004 and January 2023. Primary outcome was incident HCC. RESULTS: 12 950 patients had Fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM) (mean age 51.7 years; 41.1% male). At a median follow-up of 47.7 (IQR 23.3-72.3) months, 109 (0.8%) developed HCC. FIB-4 was below the low cut-off (<1.3 if aged <65 years and <2.0 if aged ≥65 years), between the low cut-off and <2.67, 2.67 to <3.25, and ≥3.25 in 66.3%, 23.9%, 3.4% and 6.4% of patients; the corresponding annual HCC incidence was 0.07%, 0.17%, 0.77% and 1.18%. As a stand-alone test, the annual HCC incidence exceeded 0.2% for LSM ≥10 kPa and 1% for LSM ≥20 kPa. If LSM was performed as a second step only among patients with FIB-4 above the low cut-off, the annual HCC incidence exceeded 0.2% for LSM ≥10 kPa and 1% for LSM ≥15 kPa. CONCLUSION: HCC surveillance should be offered to patients with MASLD with FIB-4 ≥3.25 or LSM ≥20 kPa. When a two-step approach is adopted, LSM ≥15 kPa in patients with increased FIB-4 predicts a high HCC risk.
引用
- Lai JC, Yang B, Lee HW, et al. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2025. PMID: 40541300. doi:10.1136/gutjnl-2025-334981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。